IRLAB Showcases Parkinson’s Pipeline and AI Discovery Advances at AD/PD 2026

The latest announcement is out from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ).

IRLAB Therapeutics will present new clinical and preclinical data at the AD/PD 2026 conference in Copenhagen, highlighting progress across its Parkinson’s disease pipeline and discovery platform. The company will showcase phase IIb data for its investigational drug pirepemat, as well as advances in its AI-driven Integrative Screening Process and real-world insights on amantadine use for levodopa-induced dyskinesias.

Phase IIb results from the REACT-PD trial indicate that pirepemat may meaningfully reduce fall frequency in Parkinson’s patients when maintained within an optimal plasma concentration range, supporting individualized dosing strategies and further development of the drug. IRLAB will also present enhancements to its AI/ML-based Integrative Screening Process, which improves behavioral phenotyping and predictive accuracy in CNS drug discovery, and share observational findings on amantadine treatment patterns that could inform future therapeutic approaches to dyskinesias.

The most recent analyst rating on ($SE:IRLAB.A) stock is a Hold with a SEK1.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.

More about IRLAB Therapeutics AB Class A

IRLAB Therapeutics AB is a Swedish biopharmaceutical company focused on discovering and developing new treatments for Parkinson’s disease and other central nervous system disorders. Listed on Nasdaq Stockholm, the company leverages an AI- and machine learning–driven phenotypic drug discovery platform to generate innovative, first-in-class candidate drugs targeting neurotransmitter dysregulation.

Average Trading Volume: 240,858

Technical Sentiment Signal: Sell

Current Market Cap: SEK131.3M

See more insights into IRLAB.A stock on TipRanks’ Stock Analysis page.